Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,096 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle Control Clear all
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye

NCT05109702
View directory record Official record
Conditions
Dry Eye
Interventions
0.25% Tanfanercept Ophthalmic Solution, Placebo
Drug
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Glendale, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 20, 2026, 9:04 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

New Functional Ingredient for Oral Care

NCT07771907
View directory record Official record
Conditions
Oral Health Related Quality of Life (OHRQoL)
Interventions
Botanical A, Botanical B, Vehicle (Placebo solution)
Dietary Supplement
Lead sponsor
Access Business Group
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 20, 2026, 9:04 AM EDT
Completed Phase 4 Interventional Results available

Osteoarthritis Knee Pain Relief Study of 0.25% 920-CGS-200

NCT03124407
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Capsaicin Topical Solution, Drug product vehicle
Drug · Other
Lead sponsor
Propella Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Clearwater, Florida • Tampa, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 20, 2026, 9:04 AM EDT
Recruiting Phase 3 Interventional

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

NCT07637734
View directory record Official record
Conditions
Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Interventions
VP-102 (US) / TO-208 (Japan), Vehicle (US) / Vehicle (Japan)
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
12
States / cities
San Diego, California • Jacksonville, Florida • Sweetwater, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 20, 2026, 9:04 AM EDT
Terminated Phase 2 Interventional Results available

Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve

NCT01886313
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Civamide Nasal Spray, Placebo
Drug
Lead sponsor
Winston Laboratories
Industry
Eligibility
21 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Santa Monica, California • Lauderdale Lakes, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 20, 2026, 9:04 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

NCT07453888
View directory record Official record
Conditions
Non-Arteritic Anterior Ischemic Optic Neuropathy
Interventions
Cenegermin, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
50 Years to 80 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
22
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 20, 2026, 9:04 AM EDT
Completed Phase 3 Interventional Results available

Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts

NCT03532776
View directory record Official record
Conditions
External Anogenital Warts
Interventions
Podofilox Gel 0.5%, Condylox Topical Gel 0.5%, Placebo Gel
Drug
Lead sponsor
Dermax SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 20, 2026, 9:04 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation

NCT05790941
View directory record Official record
Conditions
Hypotrichosis
Interventions
Latanoprost and Minoxidil
Combination Product
Lead sponsor
Aneira Pharma, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Indian Wells, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 20, 2026, 9:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction

NCT05261386
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
CBT-008
Drug
Lead sponsor
Cloudbreak Therapeutics, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 20, 2026, 9:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Norwalk Vaccine Study

NCT00806962
View directory record Official record
Conditions
Norovirus
Interventions
Adjuvant/Excipients, placebo, Norwalk VLP Vaccine
Drug · Device · Biological
Lead sponsor
LigoCyte Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 20, 2026, 9:04 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301

NCT01017146
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene foam, Vehicle Foam
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years to 45 Years
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
19
States / cities
Denver, Colorado • Miami Beach, Florida • Indianapolis, Indiana + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 20, 2026, 9:04 AM EDT
Completed Phase 3 Interventional

Phase 3 Study of EBI-005 in Dry Eye Disease

NCT01998802
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
Active Comparator EBI-005, Placebo Comparator
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
45
States / cities
Chandler, Arizona • Mesa, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 20, 2026, 9:04 AM EDT
Completed Phase 2 Interventional

Study to Determine the Effects Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region

NCT01083875
View directory record Official record
Conditions
Oral Mucositis
Interventions
amlexanox, Vehicle rinse
Drug
Lead sponsor
Access Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Mobile, Alabama • Little Rock, Arkansas • Bakersfield, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2010 · Synced Oct 20, 2026, 9:04 AM EDT
Not listed Phase 2Phase 3 Interventional

Skin Care Regimen for Improving Photoaging Signs on the Face

NCT06603857
View directory record Official record
Conditions
Improve Photoaging Signs
Interventions
CE Ferulic, Sham Comparator, 1927nm (Clear and Brilliant Perméa®)
Drug · Device
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
30 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 9:04 AM EDT
Completed Phase 2 Interventional

Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease

NCT06370039
View directory record Official record
Conditions
Dry Eye Disease
Interventions
INV-102, Vehicle
Drug
Lead sponsor
Invirsa, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Rush, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 20, 2026, 9:04 AM EDT
Completed Phase 2Phase 3 Interventional

Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency

NCT05397665
View directory record Official record
Conditions
Hereditary Neuropathy Caused by SORD Deficiency
Interventions
AT-007, Placebo
Drug
Lead sponsor
Applied Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Coral Gables, Florida • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 20, 2026, 9:04 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

NCT02938494
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-123 Lotion, Tazorac Cream, Vehicle Lotion, Vehicle Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Encinitas, California • Fremont, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 20, 2026, 9:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dosing Interval Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness

NCT02339129
View directory record Official record
Conditions
Delayed Onset Muscle Soreness
Interventions
SST-0225, Placebo
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
16 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
South Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 20, 2026, 9:04 AM EDT
Completed Phase 2 Interventional

ACTiF- Assessment of Closed Tibial Fractures

NCT00533377
View directory record Official record
Conditions
Tibial Fractures
Interventions
CP-533,536, Placebo, Standard of Care
Drug · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
17 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
11
States / cities
Wichita, Kansas • Worcester, Massachusetts • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 20, 2026, 9:04 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)

NCT03168334
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-123 Lotion, IDP-123 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 99 Years
Enrollment
801 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
41
States / cities
Mobile, Alabama • Rogers, Arkansas • Carlsbad, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 20, 2026, 9:04 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

NCT03573401
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma
Interventions
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Fountain Valley, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 20, 2026, 9:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks

NCT02601105
View directory record Official record
Conditions
Stretch Marks, Striae Distensae, Cosmetic Appearance of Stretch Marks
Interventions
Placebo Vehicle Cream, Centella Asiatica Cream
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 20, 2026, 9:04 AM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris

NCT03361345
View directory record Official record
Conditions
Postinflammatory Hyperpigmentation
Interventions
Tranexamic Acid, Vehicle
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 20, 2026, 9:04 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail

NCT01302119
View directory record Official record
Conditions
Onychomycosis of Toenails
Interventions
AN2690 Topical Solution, 5%, Solution Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
26
States / cities
Phoenix, Arizona • Novato, California • Oceanside, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 20, 2026, 9:04 AM EDT